Document is current

Article History

Accepted: 10 May 2022

First Online: 9 June 2022

Declarations

:

: TK has received honoraria for lectures from AstraZeneca, Boehringer Ingelheim, Pharmaserve Lilly, and Novo Nordisk, for advisory boards from Novo Nordisk, and has participated in sponsored studies by Eli-Lilly and Novo Nordisk; OGM has received speaker honoraria and educational grants from Sanofi, Eli Lilly, Boehringer Ingelheim and Novo Nordisk; RAA has received institutional research grants from Abbott, Bayer, Eli Lilly, NovoNordisk and Roche, and honoraria/education support/consultant from Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Menarini Pharmaceuticals, Merck Sharp & Dohme, NovoNordisk, and Takeda; XG-M has received honoraria for lectures/advisory boards from Astra-Zeneca, Boehringer-Ingelheim, Esteve, Lilly, Merck, Novo-Nordisk, and Sanofi; GD has received honoraria for lectures and financial support for research (through the University of Athens Medical School) from Abbott, Astra Zeneca, VIANEX, Pharmaserve Lilly, ELPEN, Galenica, MSD, Novartis, Novo Nordisk, and Sanofi; KK has received honoraria for lectures/advisory boards and research support from Astra Zeneca, Boehringer Ingelheim, Pharmaserve Lilly, Sanofi-Aventis, ELPEN, MSD, and Novo Nordisk; PZ declares no potential conflicts of interest that might be relevant to this work.

: No external funds were used in the preparation of this manuscript.

: TK reviewed the literature and drafted the first version of the manuscript. OGM, RAA, XG-M, PZ, GD, and KK reviewed the literature and edited the manuscript. All authors have read and approved the final version of the manuscript.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.